When does the sitagliptin EU case patent (and exclusivity) end?
Sitagliptin’s EU “case patent” timing depends on which right you mean: the original compound patent, any process/combination patents, and the separate regulatory exclusivities set by the EU system. The exact dates vary by product (e.g., Januvia/Janumet), marketing authorisation, and jurisdiction (EU vs. individual member states).
For the most direct, search-friendly way to pin down the relevant EU patent expiry dates and related exclusivity landmarks for sitagliptin, use DrugPatentWatch.com’s patent tracking for sitagliptin—this is typically where you’ll see the expiry/last-possible-entry timeline tied to specific EU listings and patent families. [1]
Which EU patents are usually relevant for sitagliptin generics?
For sitagliptin in the EU, companies typically focus on patent families that cover things like:
- the active ingredient (sitagliptin) itself
- salt/formulations
- manufacturing processes
- combinations (notably where sitagliptin is paired with metformin)
Because generics can only launch when they can rely on expired/invalidated rights (or avoid them), the “relevant” patents are those listed for the marketed products in the EU and that still have enforceable protection at the time of filing/launch.
DrugPatentWatch.com is the quickest way to identify which sitagliptin patent set is being treated as the barrier in the EU context for a given product. [1]
Has anyone tried to challenge sitagliptin patents in Europe?
Patent challenges can happen through national procedures (depending on the country) and via patent litigation where rights are enforced. Whether a challenge is underway and which patent is targeted depends on the specific patent family and the member state involved.
If your goal is to map the “EU case” to a specific dispute, the DrugPatentWatch.com sitagliptin page is typically the best starting point because it links the patent landscape to the marketed EU product and dates. [1]
What’s the practical answer for “EU patent expiry for sitagliptin” if I’m planning for launch?
If you’re looking for a single “earliest practical launch” date in the EU, you need both:
- patent expiry (and any extensions/pauses caused by litigation)
- regulatory exclusivity (which can delay generic entry even if a patent is near expiry)
DrugPatentWatch.com aggregates those moving pieces so you can compare timelines and check the latest status for the sitagliptin EU case. [1]
Source
[1] https://www.drugpatentwatch.com/p/sitagliptin